Temsirolimus not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be…”In the company’s words, NCT04433572 on ClinicalTrials.gov
- Tested for
- Peripheral Artery Disease, Critical Limb Ischemia
- Main trialPhase 3
- “A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion revascularization, and clinically relevant target lesion occlusion after revascularization of lesions below the knee in patients with symptomatic Rutherford 3-5 peripheral artery disease. The primary safety endpoint will be gathered at 1-month post-index procedure. The primary efficacy endpoint will be gathered at 6 months post-index procedure. Participants will be…”In the company’s words, NCT04433572 on ClinicalTrials.gov
Other drugs for Peripheral Artery Disease
- OrforglipronEli Lilly · Phase 3
- RetatrutideEli Lilly · Phase 3
- ClazakizumabCSL Behring · Phase 2/3
- CenvacibartRegeneron · Phase 3
- REGN9933Regeneron · Phase 3
- EtribnabdioneVivaCell Biotechnology España · Phase 2
Coming up1
- 1 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Feb 2028 | Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee | |
| Phase 1/2Authorised | not given | A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026